Literature DB >> 19582593

Positive allosteric interaction of structurally diverse T-type calcium channel antagonists.

Victor N Uebele1, Cindy E Nuss, Steven V Fox, Susan L Garson, Razvan Cristescu, Scott M Doran, Richard L Kraus, Vincent P Santarelli, Yuxing Li, James C Barrow, Zhi-Qiang Yang, Kelly-Ann S Schlegel, Kenneth E Rittle, Thomas S Reger, Rodney A Bednar, Wei Lemaire, Faith A Mullen, Jeanine E Ballard, Cuyue Tang, Ge Dai, Owen B McManus, Kenneth S Koblan, John J Renger.   

Abstract

Low-voltage-activated (T-type) calcium channels play a role in diverse physiological responses including neuronal burst firing, hormone secretion, and cell growth. To better understand the biological role and therapeutic potential of the target, a number of structurally diverse antagonists have been identified. Multiple drug interaction sites have been identified for L-type calcium channels, suggesting a similar possibility exists for the structurally related T-type channels. Here, we radiolabel a novel amide T-type calcium channel antagonist (TTA-A1) and show that several known antagonists, including mibefradil, flunarizine, and pimozide, displace binding in a concentration-dependent manner. Further, we identify a novel quinazolinone T-type antagonist (TTA-Q4) that enhanced amide radioligand binding, increased affinity in a saturable manner and slowed dissociation. Functional evaluation showed these compounds to be state-dependent antagonists which show a positive allosteric interaction. Consistent with slowing dissociation, the duration of efficacy was prolonged when compounds were co-administered to WAG/Rij rats, a genetic model of absence epilepsy. The development of a T-type calcium channel radioligand has been used to demonstrate structurally distinct TTAs interact at allosteric sites and to confirm the potential for synergistic inhibition of T-type calcium channels with structurally diverse antagonists.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19582593     DOI: 10.1007/s12013-009-9057-4

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  18 in total

1.  Nerve terminal nicotinic acetylcholine receptors initiate quantal GABA release from perisomatic interneurons by activating axonal T-type (Cav3) Ca²⁺ channels and Ca²⁺ release from stores.

Authors:  Ai-Hui Tang; Miranda A Karson; Daniel A Nagode; J Michael McIntosh; Victor N Uebele; John J Renger; Matthias Klugmann; Teresa A Milner; Bradley E Alger
Journal:  J Neurosci       Date:  2011-09-21       Impact factor: 6.167

2.  Essential thalamic contribution to slow waves of natural sleep.

Authors:  François David; Joscha T Schmiedt; Hannah L Taylor; Gergely Orban; Giuseppe Di Giovanni; Victor N Uebele; John J Renger; Régis C Lambert; Nathalie Leresche; Vincenzo Crunelli
Journal:  J Neurosci       Date:  2013-12-11       Impact factor: 6.167

3.  Comparative analysis of inactivated-state block of N-type (Ca(v)2.2) calcium channels.

Authors:  Timothy A Vortherms; Andrew M Swensen; Wende Niforatos; James T Limberis; Torben R Neelands; Richard S Janis; Rama Thimmapaya; Diana L Donnelly-Roberts; Marian T Namovic; Di Zhang; C Brent Putman; Ruth L Martin; Carol S Surowy; Michael F Jarvis; Victoria E Scott
Journal:  Inflamm Res       Date:  2011-03-11       Impact factor: 4.575

Review 4.  Cav3 T-type channels: regulators for gating, membrane expression, and cation selectivity.

Authors:  A Senatore; W Guan; J D Spafford
Journal:  Pflugers Arch       Date:  2014-02-11       Impact factor: 3.657

Review 5.  Modulation of T-type calcium channels by bioactive lipids.

Authors:  Jean Chemin; Magali Cazade; Philippe Lory
Journal:  Pflugers Arch       Date:  2014-02-16       Impact factor: 3.657

6.  Discovery of 4,4-Disubstituted Quinazolin-2-ones as T-Type Calcium Channel Antagonists.

Authors:  James C Barrow; Kenneth E Rittle; Thomas S Reger; Zhi-Qiang Yang; Phung Bondiskey; Georgia B McGaughey; Mark G Bock; George D Hartman; Cuyue Tang; Jeanine Ballard; Yuhsin Kuo; Thomayant Prueksaritanont; Cindy E Nuss; Scott M Doran; Steven V Fox; Susan L Garson; Richard L Kraus; Yuxing Li; Michael J Marino; Valerie Kuzmick Graufelds; Victor N Uebele; John J Renger
Journal:  ACS Med Chem Lett       Date:  2010-02-01       Impact factor: 4.345

Review 7.  Low threshold T-type calcium channels as targets for novel epilepsy treatments.

Authors:  Kim L Powell; Stuart M Cain; Terrance P Snutch; Terence J O'Brien
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

8.  Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents.

Authors:  Zhi-Qiang Yang; Kelly-Ann S Schlegel; Youheng Shu; Thomas S Reger; Rowena Cube; Christa Mattern; Paul J Coleman; Jim Small; George D Hartman; Jeanine Ballard; Cuyue Tang; Yuhsin Kuo; Thomayant Prueksaritanont; Cindy E Nuss; Scott Doran; Steve V Fox; Susan L Garson; Yuxing Li; Richard L Kraus; Victor N Uebele; Adekemi B Taylor; Wei Zeng; Wei Fang; Cynthia Chavez-Eng; Matthew D Troyer; Julie Ann Luk; Tine Laethem; William O Cook; John J Renger; James C Barrow
Journal:  ACS Med Chem Lett       Date:  2010-08-24       Impact factor: 4.345

9.  Verapamil block of T-type calcium channels.

Authors:  Pamela Bergson; Gregory Lipkind; Steven P Lee; Mark-Eugene Duban; Dorothy A Hanck
Journal:  Mol Pharmacol       Date:  2010-12-13       Impact factor: 4.436

Review 10.  T-type Ca2+ channels in absence epilepsy.

Authors:  Eunji Cheong; Hee-Sup Shin
Journal:  Pflugers Arch       Date:  2014-02-13       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.